NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/12/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization67.67 mln
Float95.61 mln
Earnings Date05/13/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.97
Highly reliable
Relative Strength
2
/ 100
Severely lagging
Debt / Equity
0.18
Very low leverage
ROE
-101
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
aTyr Pharma is a San Diego-based clinical-stage biotech company focused on treating serious lung and inflammatory diseases. Its most advanced drug candidate, efzofitimod, is currently being tested in multiple clinical trials for pulmonary sarcoidosis and related lung conditions, with a partnership in place for its development and commercialization in Japan. The company also has earlier-stage programs targeting liver disease and fibrosis, and its work is rooted in research into a class of proteins that play a broader biological role than scientists originally recognized.